{"doc_id": "33350698", "type of study": "Therapy", "title": "", "abstract": "Remdesivir in The Treatment of COVID-19.\nAccording to this study: The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19.A variety of therapeutic approaches are needed to continue to improve outcomes in COVID-19 patients.\nCopyright \u00a9 2021 Wolters Kluwer Health, Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 39}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Remdesivir in The Treatment of COVID-19 .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 39}], "Intervention": [{"term": "Remdesivir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "According to this study : The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19 . A variety of therapeutic approaches are needed to continue to improve outcomes in COVID-19 patients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "superior", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 62}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Wolters Kluwer Health , Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}